Pfizer arthritis drug meets main goals of trial
Pfizer said that its experimental rheumatoid arthritis drug met the main goals of a late-stage clinical trial, a welcome boost for the world's largest drugmaker as it seeks new products to offset those that are losing patent protection.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that virtually the same percentage of surveyed rheumatologists selected Amgen/Pfizer/Takeda's Enbrel and Abbott/Eisai's Humira as the most efficacious agent for the treatment of rheumatoid arthritis.